Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month High – Should You Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price hit a new 52-week high on Monday . The company traded as high as $39.39 and last traded at $39.25, with a volume of 37092 shares. The stock had previously closed at $38.55.

Analyst Ratings Changes

Several analysts recently issued reports on SUPN shares. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Trading Down 0.7 %

The company’s 50 day moving average is $36.98 and its 200-day moving average is $34.32. The stock has a market cap of $2.16 billion, a PE ratio of 36.59 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.29) earnings per share. As a group, analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Stephens Investment Management Group LLC boosted its holdings in shares of Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares during the period. Pacer Advisors Inc. lifted its holdings in Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Geode Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 1.1% during the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after purchasing an additional 7,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after purchasing an additional 91,354 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.